Borderline lepromatous leprosy

Borderline lepromatous leprosy
Synonyms	BL leprosy
Pronounce	N/A
Specialty	N/A
Symptoms	Skin lesions, nerve damage, muscle weakness
Complications	Peripheral neuropathy, disability
Onset	Gradual
Duration	Chronic
Types	N/A
Causes	Mycobacterium leprae infection
Risks	Close contact with untreated cases, genetic susceptibility
Diagnosis	Skin biopsy, slit-skin smear
Differential diagnosis	Tuberculoid leprosy, lepromatous leprosy, sarcoidosis
Prevention	BCG vaccine, avoiding close contact with untreated individuals
Treatment	Multidrug therapy (MDT) including dapsone, rifampicin, and clofazimine
Medication	Dapsone, rifampicin, clofazimine
Prognosis	Variable, depends on early diagnosis and treatment
Frequency	Rare
Deaths	Rare, but can lead to significant disability if untreated

Borderline lepromatous leprosy (also known as BL leprosy) is a type of leprosy, a chronic infectious disease caused by the bacterium Mycobacterium leprae. This form of leprosy is characterized by numerous skin lesions, nerve damage, and a high bacterial load.

Etiology

Borderline lepromatous leprosy is caused by Mycobacterium leprae, a slow-growing bacterium that primarily affects the skin and peripheral nerves. The bacterium is transmitted through respiratory droplets or direct contact with an infected person.

Clinical Features

Patients with borderline lepromatous leprosy typically present with numerous skin lesions, including nodules, plaques, and macules. The lesions are often symmetrically distributed and may be either hypo- or hyperpigmented. Nerve involvement is common and can lead to sensory and motor deficits.

Diagnosis

The diagnosis of borderline lepromatous leprosy is primarily based on clinical findings. Skin biopsy and histopathology can confirm the diagnosis. The presence of numerous acid-fast bacilli in the skin and nerves is characteristic of this form of leprosy.

Treatment

Treatment of borderline lepromatous leprosy involves multi-drug therapy, typically including dapsone, rifampicin, and clofazimine. Early treatment is crucial to prevent permanent nerve damage and disability.

Epidemiology

Borderline lepromatous leprosy is more common in areas where leprosy is endemic, such as India, Brazil, and parts of Africa. However, it can occur in any part of the world. The disease affects both adults and children, and there is no known gender predilection.

See Also

• Leprosy
• Tuberculoid leprosy
• Lepromatous leprosy
• Mycobacterium leprae

References

   This article is a medical stub. You can help WikiMD by expanding it!